About Syngenit Injectables Plus
Syngenit™ Injectables Plus combines Bone Marrow Aspirate Concentrate (BMAC) with fibrin glue. It can be administered either as an injection or as a surgical procedure depending on the condition being treated.
Overview as a Percutaneous Procedure
The osteochondral defect is identified prior to the surgery using Magnetic Resonance Imaging (MRI). An arthroscopic procedure may also be used to verify the defect is suitable for this treatment.
Bone Marrow Aspirate (BMA) is harvested from the patient and used to produce Bone Marrow Aspirate Concentrate (BMAC) which contains the stem cells.
The BMAC is combined with sodium hyaluronate to form a viscous mixture.
The BMAC and sodium hyaluronate are injected into the affected joint.
Overview as a Surgical Procedure
The osteochondral defect is identified prior to the surgery using Magnetic Resonance Imaging (MRI). An arthroscopic procedure may also be used to verify the defect is suitable for this treatment.
Bone Marrow Aspirate (BMA) is harvested from the patient and used to produce Bone Marrow Aspirate Concentrate (BMAC) which contains the stem cells.
The BMAC is conbined with fibrin glue to form a viscous injectable material. This is injected into the prepared defect.
Once the stem cells + fibrin glue have been placedinto the defect, fibrin glue ‘cap’ seals them in.
Syngenit Injectables Plus Patient Leaflet
Adobe Acrobat document [280.2 KB]
Print 